Skip to content

A multi-center study of ultra-early cluster therapy for acute pancreatitis

A multi-center study of ultra-early cluster therapy for acute pancreatitis

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500108733
Enrollment
Unknown
Registered
2025-09-04
Start date
2025-09-08
Completion date
Unknown
Last updated
2025-09-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute pancreatitis

Interventions

Intervention group:Ultra-early preventive fluid resuscitation cluster treatment plan for acute pancreatitis
Control group:Conventional treatment protocol (non-cluster treatment protocol)

Sponsors

Rongxian People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Patients who meet the clinical diagnosis of the Guidelines for Diagnosis and Treatment of Acute Pancreatitis in China (Shenyang, 2019) and are diagnosed with mild acute pancreatitis (MAP) or moderately severe acute pancreatitis (MSAP); 2. Onset time = 18 years old; 3. No fluid resuscitation was performed before admission (pre-hospital and out-of-hospital infusion volume < 500ml/24h).

Exclusion criteria

Exclusion criteria: 1. Patients with confirmed or suspected malignant tumor; 2. Patients with immunosuppression had used or were using immunosuppressants within 30 days, or had used glucocorticoids for more than 3 weeks within 60 days, or had white blood cells less than 0.5 × 10^9/L, or platelets less than 25 × 10^9/L; 3. Patients had severe comorbidities that might affect the outcome or safety of the study, including anemia (hemoglobin < 90 G/L), chronic renal insufficiency (EGFR < 60 ml/min/1.73 m ²), liver cirrhosis, severe chronic lung disease (e.g., GOLD stage III or IV chronic obstructive pulmonary disease, idiopathic pulmonary fibrosis, bronchiectasis, or cystic fibrosis, etc.), severe cardiovascular disease (e. NYHA class ? or ? heart failure, acute coronary syndrome, severe valvular disease within 3 months); 4. Pregnant or lactating women; 5. Refuse to be enrolled or give up treatment.

Design outcomes

Primary

MeasureTime frame
SAP incidence;28-day case fatality;

Secondary

MeasureTime frame
Complication rate;Cost of treatment;Incidence of fluid overload;Incidence of requiring invasive mechanical ventilation;Incidence of requiring blood purification therapy;Total hospitalization days;

Countries

China

Contacts

Public ContactYu Wang

Rongxian People's Hospital

8088978@qq.com+86 189 9005 0096

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026